Business
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margin guidance. A copy of the presentation and a replay of the webcast are available at investors.biomarin.com.\n\n \n \n \n \n \n \n\n \n\"Over the last 9 months, we have undertaken the transformation of BioMarin's operations and ways of working with the goal of accelerating and delivering substantial value to all our stakeholders – patients, employees and shareholders,\" said Mr. Hardy. \"Our new corporate strategy harnesses BioMarin's unique capabilities creating and leading new therapeutic markets around the world to deliver innovative medicines to the patients we serve. We are confident in our ability to realize the ambitious plans outlined today and excited to deliver on our new vision for BioMarin's future.\"\nCorporate Strategy\nThe company reviewed BioMarin's differentiated strategy including its new company structure and updated organizational model, now built around three business units, Enzyme Therapies, Skeletal Conditions and ROCTAVIAN®, designed to support the focus on sustainable growth. The updated corporate strategy also includes the implementation of a $500 million cost transformation program that will contribute to Non-GAAP Operating margin targets set for 2026 and beyond. \nValue Commitment\nBioMarin provided an overview of its long-term financial outlook, based on its strategic plan to drive revenue growth and expand Non-GAAP Operating Margin. The summary table below includes the company's full year 2024 guidance, reaffirmed today, and the newly introduced outlook for 2026 with respect to Non-GAAP Operating Margin and other metrics for 2027, shared at BioMarin's Investor Day.\nItem\nFY 2024 (reaffirmed)\nFY 2027\nTotal Revenues\n$2.750B to $2.825B\n$4B\nNon-GAAP Operating Margin (1)\n26% to 27%\nLow-to-mid 40%s starting with 40% in 2026\nNon-GAAP Diluted EPS (1)(2)\n$3.10 to $3.25\nN/A\nOperating Cash flow\nN/A\n$1.25B+ \n(1)\nRefer to Non-GAAP Information beginning on page 4 of this press release for the definitions of No...